The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Immunotherapy


Psychiatry related information on Immunotherapy


High impact information on Immunotherapy

  • This review primarily focuses on the cellular and molecular mechanisms of regulation by CTLA-4 and its manipulation as a strategy for tumor immunotherapy [10].
  • Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes [11].
  • Immunotherapy for allergic rhinitis [12].
  • RESULTS: Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it [13].
  • We compared this regimen with immunotherapy using insect venoms or placebo in groups of 20 patients matched for history and sensitivity, as judged by venom skin test, histamine release and IgE antibody to venom [14].

Chemical compound and disease context of Immunotherapy


Biological context of Immunotherapy

  • Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy [20].
  • We conclude that resistance to death receptor-induced apoptosis is crucial for the efficient induction of a protective immune response, and that Bis VIII-based immunotherapies have to be applied under well-controlled conditions to avoid the induction of immune incompetence and the inability to respond to pathogen infection [21].
  • The HSPs have thus become targets for rational anti-cancer drug design: HSP90 inhibitors are currently showing much promise in clinical trials, whereas the increased expression of HSPs in tumors is forming the basis of chaperone-based immunotherapy [22].
  • Whether the inhibition of Th2 responses without concurrent downregulation of Th1 responses will be sufficient for allergic immunotherapy, particularly for atopic dermatitis and asthma, is an important but unresolved issue [23].
  • These derivatives can be engineered to contain relevant T cell epitopes and to maintain those sequence motifs which are required for inducing protective antibody responses and therefore hold great promise for improving allergen-specific immunotherapy [24].

Anatomical context of Immunotherapy


Associations of Immunotherapy with chemical compounds


Gene context of Immunotherapy


Analytical, diagnostic and therapeutic context of Immunotherapy


  1. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. Lamm, D.L., Blumenstein, B.A., Crawford, E.D., Montie, J.E., Scardino, P., Grossman, H.B., Stanisic, T.H., Smith, J.A., Sullivan, J., Sarosdy, M.F. N. Engl. J. Med. (1991) [Pubmed]
  2. Ragweed immunotherapy in adult asthma. Creticos, P.S., Reed, C.E., Norman, P.S., Khoury, J., Adkinson, N.F., Buncher, C.R., Busse, W.W., Bush, R.K., Gadde, J., Li, J.T. N. Engl. J. Med. (1996) [Pubmed]
  3. Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. Murray, H.W., Rubin, B.Y., Masur, H., Roberts, R.B. N. Engl. J. Med. (1984) [Pubmed]
  4. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Fontaine, P., Roy-Proulx, G., Knafo, L., Baron, C., Roy, D.C., Perreault, C. Nat. Med. (2001) [Pubmed]
  5. Current progress in beta-amyloid immunotherapy. Schenk, D., Hagen, M., Seubert, P. Curr. Opin. Immunol. (2004) [Pubmed]
  6. Induction of tumor immunity by autologous B lymphoma cells expressing a genetically engineered idiotype. Selmayr, M., Strehl, J., Kremer, J.P., Kremmer, E., Doenecke, A., Hallek, M., Menzel, H., Thielemans, K., Thierfelder, S., Mocikat, R. Gene Ther. (1999) [Pubmed]
  7. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., Maes, M. Journal of clinical psychopharmacology. (2002) [Pubmed]
  8. Albert Léon Charles Calmette (1863-1933) and the antituberculous BCG vaccination. Chung, K.T., Biggers, C.J. Perspect. Biol. Med. (2001) [Pubmed]
  9. Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatment. Shah, S.C., Kusiak, A., O'donnell, M.A. Comput. Biol. Med. (2006) [Pubmed]
  10. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Chambers, C.A., Kuhns, M.S., Egen, J.G., Allison, J.P. Annu. Rev. Immunol. (2001) [Pubmed]
  11. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Rosenberg, S.A., Lotze, M.T. Annu. Rev. Immunol. (1986) [Pubmed]
  12. Immunotherapy for allergic rhinitis. Adkinson, N.F. N. Engl. J. Med. (1999) [Pubmed]
  13. Long-term clinical efficacy of grass-pollen immunotherapy. Durham, S.R., Walker, S.M., Varga, E.M., Jacobson, M.R., O'Brien, F., Noble, W., Till, S.J., Hamid, Q.A., Nouri-Aria, K.T. N. Engl. J. Med. (1999) [Pubmed]
  14. A controlled trial of immunotherapy in insect hypersensitivity. Hunt, K.J., Valentine, M.D., Sobotka, A.K., Benton, A.W., Amodio, F.J., Lichtenstein, L.M. N. Engl. J. Med. (1978) [Pubmed]
  15. Skeletal and soft tissue sarcomas. Treatment with adjuvant immunotherapy. Townsend, C.M., Eilber, F.R., Morton, D.L. JAMA (1976) [Pubmed]
  16. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. Karanikas, V., Hwang, L.A., Pearson, J., Ong, C.S., Apostolopoulos, V., Vaughan, H., Xing, P.X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., McKenzie, I.F. J. Clin. Invest. (1997) [Pubmed]
  17. Letter: 5-Fluorouracil versus immunotherapy for non-clinical vaginal cancer. Hull, M.G., Bowen-Simpkins, P., Paintin, D.B. Lancet (1976) [Pubmed]
  18. Immunotherapy of non-clinical vaginal cancer. Guthrie, D., Way, S. Lancet (1975) [Pubmed]
  19. Complications of cancer immunotherapy with levamisole. Parkinson, D.R., Cano, P.O., Jerry, L.M., Capek, A., Shibata, H.R., Mansell, P.W., Lewis, M.G., Marquis, G. Lancet (1977) [Pubmed]
  20. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. Colella, T.A., Bullock, T.N., Russell, L.B., Mullins, D.W., Overwijk, W.W., Luckey, C.J., Pierce, R.A., Restifo, N.P., Engelhard, V.H. J. Exp. Med. (2000) [Pubmed]
  21. Sensitizing antigen-specific CD8+ T cells for accelerated suicide causes immune incompetence. Wasem, C., Arnold, D., Saurer, L., Corazza, N., Jakob, S., Herren, S., Vallan, C., Mueller, C., Brunner, T. J. Clin. Invest. (2003) [Pubmed]
  22. Heat shock proteins in cancer: chaperones of tumorigenesis. Calderwood, S.K., Khaleque, M.A., Sawyer, D.B., Ciocca, D.R. Trends Biochem. Sci. (2006) [Pubmed]
  23. Allergy immunotherapy and inhibition of Th2 immune responses: a sufficient strategy? Lewis, D.B. Curr. Opin. Immunol. (2002) [Pubmed]
  24. From allergen structure to new forms of allergen-specific immunotherapy. Valenta, R., Kraft, D. Curr. Opin. Immunol. (2002) [Pubmed]
  25. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., Tedder, T.F. J. Exp. Med. (2004) [Pubmed]
  26. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. Ettinghausen, S.E., Puri, R.K., Rosenberg, S.A. J. Natl. Cancer Inst. (1988) [Pubmed]
  27. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. de Rijke, B., van Horssen-Zoetbrood, A., Beekman, J.M., Otterud, B., Maas, F., Woestenenk, R., Kester, M., Leppert, M., Schattenberg, A.V., de Witte, T., van de Wiel-van Kemenade, E., Dolstra, H. J. Clin. Invest. (2005) [Pubmed]
  28. Letter: Immunotherapy with levamisole. Arnold, H.L. N. Engl. J. Med. (1976) [Pubmed]
  29. A chimeric human-cat fusion protein blocks cat-induced allergy. Zhu, D., Kepley, C.L., Zhang, K., Terada, T., Yamada, T., Saxon, A. Nat. Med. (2005) [Pubmed]
  30. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. McLaughlin, C.A., Schwartzman, S.M., Horner, B.L., Jones, G.H., Moffatt, J.G., Nestor, J.J., Tegg, D. Science (1980) [Pubmed]
  31. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. Cameron, R.B., Spiess, P.J., Rosenberg, S.A. J. Exp. Med. (1990) [Pubmed]
  32. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. Gober, H.J., Kistowska, M., Angman, L., Jenö, P., Mori, L., De Libero, G. J. Exp. Med. (2003) [Pubmed]
  33. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Boël, P., Wildmann, C., Sensi, M.L., Brasseur, R., Renauld, J.C., Coulie, P., Boon, T., van der Bruggen, P. Immunity (1995) [Pubmed]
  34. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. Fluckiger, A.C., Durand, I., Banchereau, J. J. Exp. Med. (1994) [Pubmed]
  35. Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4). Widmer, M.B., Acres, R.B., Sassenfeld, H.M., Grabstein, K.H. J. Exp. Med. (1987) [Pubmed]
  36. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. Gavett, S.H., O'Hearn, D.J., Li, X., Huang, S.K., Finkelman, F.D., Wills-Karp, M. J. Exp. Med. (1995) [Pubmed]
  37. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Prakken, B.J., Samodal, R., Le, T.D., Giannoni, F., Yung, G.P., Scavulli, J., Amox, D., Roord, S., de Kleer, I., Bonnin, D., Lanza, P., Berry, C., Massa, M., Billetta, R., Albani, S. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  38. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. Ferreira, F., Hirtenlehner, K., Jilek, A., Godnik-Cvar, J., Breiteneder, H., Grimm, R., Hoffmann-Sommergruber, K., Scheiner, O., Kraft, D., Breitenbach, M., Rheinberger, H.J., Ebner, C. J. Exp. Med. (1996) [Pubmed]
  39. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Straus, S.E., Corey, L., Burke, R.L., Savarese, B., Barnum, G., Krause, P.R., Kost, R.G., Meier, J.L., Sekulovich, R., Adair, S.F. Lancet (1994) [Pubmed]
  40. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Restifo, N.P., Haworth, L.R., Seipp, C.A., Freezer, L.J., Morton, K.E., Mavroukakis, S.A., Duray, P.H., Steinberg, S.M., Allison, J.P., Davis, T.A., Rosenberg, S.A. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  41. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Beyer, M., Kochanek, M., Darabi, K., Popov, A., Jensen, M., Endl, E., Knolle, P.A., Thomas, R.K., von Bergwelt-Baildon, M., Debey, S., Hallek, M., Schultze, J.L. Blood (2005) [Pubmed]
  42. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. Vachino, G., Gelfand, J.A., Atkins, M.B., Tamerius, J.D., Demchak, P., Mier, J.W. Blood (1991) [Pubmed]
WikiGenes - Universities